摘要
目的：探讨早期宫颈癌患者术前炎性标志物与疾病进展和预后的关系。方法根据疾病进展情况，将68例接受手术治疗的早期宫颈癌患者分为疾病稳定（stable disease，SD）组（n=56）和疾病进展（progres-sive disease，PD）组（n=12），比较两组患者术前的C反应蛋白（C-reactive protein，CRP）水平、中性粒细胞与淋巴细胞比率（neutrophil-lymphocyte ratio，NLR）、血小板与淋巴细胞比率（platelet-lymphocyte ratio，PLR），并对具有统计学意义（P＜0.05）的指标进行分析，以明确其对疾病无进展生存时间（progression-free survival，PFS）的影响。结果三个炎性指标中仅NLR与疾病进展具有相关性（P＜0.05），中位NLR值为3.2（0.25～43.3）。NLR＜3.2组患者及NLR≥3.2组患者的中位PFS分别为68个月和43个月，差异具有统计学意义（P=0.015）。结论早期宫颈癌患者的术前NLR升高提示患者的PFS较短，预后较差；术前NLR作为患者的预后指标具有一定的临床意义。
Objective To study the relation between early-stage cervical carcinoma and pre-operative inflamma-tion biomarkers. Method Sixty-eight patients with early-stage cervical carcinoma, who underwent surgery in our hos-pital, were enrolled and grouped as stable disease group （SD group; n = 56） and progressive disease group （PD group; n = 12） based on individual disease conditions during follow up. The levels of pre-operative CRP （C-reactive protein）, ratio of NLR （neutrophil- lymphocyte） and PLR （platelet- lymphocyte） in the two groups were compared, and significant measurement was evaluated in respect of PFS. Result NLR ratio is the only measurement correlating with PFS （P 〈 0.05）, with a median NLR of 3.2, and a range of 0.25- 43.30. The median of PFS was 68 months in the lower NLR group （NLR 〈 3.2）, compared with 43 months in the higher NLR group （≥ 3.2） （P = 0.015）. Conclu-sion Pre-operative NLR may be a biomarker to assess the PFS of early-stage cervical carcinoma, higher NLR indi-cates a worse prognosis.
出处
《癌症进展》
2015年第3期338-341,345,共5页
Oncology Progress
关键词
早期宫颈癌
炎性标志物
预后
early-stage cervical carcinoma
inflammation biomarkers
prognosis
